Search results for "Axe"

showing 10 items of 550 documents

Sex-related effects in the superhydrophobic properties of damselfly wings in young and old Calopteryx splendens.

2013

Numerous sex-related morphological adaptations are connected to reproductive behavior in animals. For example, females of some insect species can submerge during oviposition, which may lead to sex-related adaptations in the hydrophobicity (water-repellency) due to specialization of certain morphological structures. On the other hand, ageing can cause changes in hydrophobicity of the surface, because the morphological structures can wear with age. Here, we investigated sex-and age-related differences in wing hydrophobicity and in morphology (spine density, wax cover characteristics, size of females' pseudopterostigma) potentially related to hydrophobicity of Calopteryx splendens damselflies.…

MaleSexual ReproductionAgingAnatomy and PhysiologyOdonataInsectOdonataBehavioral EcologyDamselflyMorphogenesisWings AnimalBiomechanicsYoung femaleYoung malemedia_commonSex CharacteristicsMultidisciplinarySexual DifferentiationEcologyAnimal BehaviorEcologyPhysicsQRSex relatedBiomechanical PhenomenaMedicineFemaleHydrophobic and Hydrophilic InteractionsResearch ArticleBiotechnologyanimal structuresmedia_common.quotation_subjectScienceMaterials ScienceBiophysicsBiologyBiomaterialsAnimalsBiologyAnalysis of VarianceEvolutionary BiologyWingCryoelectron MicroscopyReproductive SystemReproductive behaviorbiology.organism_classificationNanostructuresEvolutionary EcologyWaxesZoologyEntomologyDevelopmental BiologyPLoS ONE
researchProduct

Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective,…

2007

OBJECTIVE - It is still controversial whether sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) are equally effective in patients with diabetes. In these patients, multiple individual variables may be responsible for neointimal hyperplasia, thus making difficult the comparison of the two drug-eluting stents (DES). RESEARCH DESIGN AND METHODS - We designed a prospective, randomized study to compare the efficacy in prevention of restenosis of SES and PES, both implanted in the same diabetic patient with multiple de novo coronary artery lesions undergoing elective percutaneous coronary intervention. We enrolled 60 patients with diabetes with at least two significant de novo angi…

MaleSirolimusPaclitaxel-Eluting StentPaclitaxelAntineoplastic AgentsCoronary DiseaseDrug-Eluting StentsMiddle AgedCoronary AngiographySirolimus; Paclitaxel-Eluting Stent; Coronary Artery LesionsAnti-Bacterial AgentsCoronary RestenosisDiabetic Patient.Diabetes Mellitus Type 1Diabetes Mellitus Type 2Coronary Artery LesionsHumansFemalerestenosiProspective StudiesDiabetic AngiopathiesAgedDiabetes care
researchProduct

Long-term follow-up after drug eluting stent implantation in left main trifurcations

2009

Aims: Trifurcation lesions, which are mostly observed in distal left main (LM), represent a technical challenge for interventional cardiologists. We sought to determine the feasibility and long-term clinical outcome of drug eluting stent (DES) implantation in patients with LM coronary trifurcation lesions. Methods and results: All patients with clinically significant de novo LM trifurcation lesions, who refused coronary artery bypass surgery and were considered eligible for percutaneous coronary intervention (PCI), were consecutively enrolled in this study from November 2005 to February 2007. Eleven patients (65±9 years, 91% men) met all the inclusion criteria and underwent LM trifurcation …

MaleTarget lesionmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentTrifurcation lesions.Coronary DiseaseCoronary AngiographyCoronary artery bypass surgeryClinical endpointStentHumansMedicineMyocardial infarctionAgedSirolimusbusiness.industryAngioplastyStentPercutaneous coronary interventionDrug-Eluting StentsEquipment DesignMiddle Agedmedicine.diseaseCoronary VesselsDESTubulin ModulatorsSurgeryDrug-eluting stentConventional PCIFemaleRadiologyCardiology and Cardiovascular MedicinebusinessImmunosuppressive AgentsFollow-Up Studies
researchProduct

Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions

2021

Purpose: Reporting outcomes with a new generation paclitaxel eluting balloon (Luminor®; iVascular, Vascular, S.L.U., Barcelona, Spain) in the popliteal district. Endovascular treatment of popliteal artery atherosclerotic disease is still debated without definitive evidences. Methods: From January to June 2019, patients’ data presenting popliteal artery atherosclerotic diseases and treated with the Luminor® (iVascular) drug eluting balloon (DEB) were prospectively collected. Critical limb ischemia (CLI) or severe claudication associated with popliteal artery stenosis >50% were the inclusion criteria. Measured outcomes were technical success, early and late results; including mortality, mo…

MaleTime Factorsmedicine.medical_treatmentConstriction Pathologic030204 cardiovascular system & hematologySeverity of Illness IndexSettore MED/22 - Chirurgia Vascolare030218 nuclear medicine & medical imaging0302 clinical medicineRestenosisCoated Materials BiocompatibleIschemiaRecurrenceMedicineProspective StudiesAged 80 and overEndovascularCritical limb ischemiaGeneral MedicineEquipment DesignLimb SalvagePlaque AtheroscleroticTreatment OutcomeFemalemedicine.symptomCardiology and Cardiovascular MedicineVascular Access Devicesmedicine.medical_specialtyPaclitaxelPopliteal arteryCritical IllnessDrug eluting balloonAmputation Surgical03 medical and health sciencesPeripheral Arterial Diseasemedicine.arteryAngioplastyHumansVascular PatencyAgedbusiness.industryAngioplastyCardiovascular AgentsCritical limb ischemiaPerioperativeIntermittent Claudicationmedicine.diseasePopliteal arterySurgeryStenosisAmputationSurgerybusinessClaudicationAngioplasty Balloon
researchProduct

Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin

2009

The dual role of the inducible NO synthase (iNOS) and NO signaling in head and neck squamous cell carcinoma (HNSCC) is a complex and can both promote or inhibit tumor progression. However, the underlying molecular mechanisms are not yet resolved in detail. We show for the first time that conditions, favoring low NO levels conferred resistance against cisplatin/taxol-induced apoptosis in HNSCC cell lines. Cytoprotection was mediated by survivin, because we observed its upregulation subsequent to low doses of the NO donors S-nitroso-N-acetyl-penicillamine (SNAP) and sodium nitroprusside (SNP) or ectopic expression of physiologic amounts of iNOS. Also, RNAi-mediated depletion of survivin block…

MaleUmbilical VeinsCancer ResearchSurvivinFluorescent Antibody TechniqueNitric Oxide Synthase Type IIApoptosisp38 Mitogen-Activated Protein KinasesInhibitor of Apoptosis ProteinsImmunoenzyme TechniquesPhosphatidylinositol 3-Kinaseschemistry.chemical_compoundLY294002Enzyme InhibitorsRNA Small InterferingAged 80 and overReverse Transcriptase Polymerase Chain ReactionCell CycleMiddle AgedCell cycleOncologyHead and Neck NeoplasmsCarcinoma Squamous CellFemaleMicrotubule-Associated ProteinsNitroprussidePaclitaxelImmunoblottingAntineoplastic AgentsS-Nitroso-N-AcetylpenicillamineBiologyCell LineDownregulation and upregulationSurvivinmedicineHumansNitric Oxide DonorsRNA MessengerneoplasmsProtein kinase BNitritesPI3K/AKT/mTOR pathwayAgedmedicine.diseaseAntineoplastic Agents PhytogenicHead and neck squamous-cell carcinomachemistryDrug Resistance NeoplasmTumor progressionImmunologyCancer researchEndothelium VascularCisplatinProto-Oncogene Proteins c-aktInternational Journal of Cancer
researchProduct

AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC

2019

<b><i>Introduction:</i></b> Androgen receptor variant 7 (AR-V7) plays an important role in the progression of castration-resistant prostate cancer (CRPC) and has shown potential as a predictive biomarker in circulating tumour cells (CTCs) isolated from the bloodstream in terms of a liquid biopsy. Studies have shown that AR-V7 is a potential surrogate for selecting drug classes for systemic treatment by detecting nuclear AR-V7 by immunofluorescence or measuring AR-V7 messenger RNA by quantitative PCR. Here, we assessed the predictive value of AR-V7 detected by classical immunohistochemistry (IHC) for treatment response. <b><i>Methods:</i></b> C…

MaleUrology030232 urology & nephrologyAntineoplastic AgentsDocetaxel03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineCell Line TumormedicineHumansEnzalutamideProspective StudiesLiquid biopsyAgedAged 80 and overbusiness.industryAndrogen AntagonistsNeoplastic Cells CirculatingPrognosismedicine.diseaseAndrogen receptorProstatic Neoplasms Castration-ResistantTreatment OutcomeDocetaxelchemistryReceptors AndrogenCabazitaxel030220 oncology & carcinogenesisCancer researchBiomarker (medicine)ImmunohistochemistryTaxoidsbusinessmedicine.drugUrologia Internationalis
researchProduct

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxe…

2010

There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cyclophosphamide prednisolone combination in this setting.From 2005 to 2010, patients with HRPC who failed at least docetaxel-based chemotherapy were proposed metronomic cyclophosphamide-prednisolone regimen, and were prospectively registered. Twenty-three patients received 50 mg cyclophosphamide and 10 mg prednisolone per os daily until disease progression. Treatment tolerance and efficacy on PSA decrease and pain were studied.Metronomic cyclophospham…

Male[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Antineoplastic Combined Chemotherapy ProtocolsMESH: Treatment FailurePrednisoloneMESH : MaleMESH : PrednisoloneMESH: TaxoidsMESH : AgedMESH : Prospective StudiesDocetaxelMESH : Treatment OutcomeMESH : Treatment FailureMESH: Aged 80 and overAntineoplastic Combined Chemotherapy ProtocolsHumans[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : Middle AgedProspective StudiesTreatment FailureMESH : Prostate-Specific AntigenMESH : Aged 80 and overMESH : TaxoidsCyclophosphamideMESH : Cyclophosphamidehealth care economics and organizationsAgedMESH: Treatment OutcomeAged 80 and overMESH: AgedMESH: HumansMESH: Middle AgedMESH : HumansProstatic NeoplasmsMESH: CyclophosphamideMiddle AgedProstate-Specific AntigenMESH: MaleMESH: Prospective StudiesMESH: Prostate-Specific AntigenMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeMESH: Prostatic Neoplasms[SDV.IMM]Life Sciences [q-bio]/ImmunologyTaxoidsMESH: PrednisoloneMESH : Prostatic Neoplasms
researchProduct

Exploratory study of the hoaxes spread via WhatsApp in Spain to prevent and/or cure COVID-19

2021

Objective: To review the hoaxes’ characteristics spread through WhatsApp in Spain during COVID-19 lockdown and identify what kind of substances were promoted for consumption or application. Method: A phone number was activated to receive hoaxes via WhatsApp. A total of 2353 messages were collected, and among those 584 different hoaxes were identified and validated, between March 18 and April 18, 2020. From these 584 hoaxes, a sub-sample of 126 was selected, exclusively related to the object of study, and a content analysis table with fourteen registration fields was applied. Besides, the averages and medians of the quantitative fields were extracted. Results: Most of the messages received w…

Malemedicine.medical_specialtyDeceptionCoronavirus disease 2019 (COVID-19)OriginalWhatsAppExploratory researchSaludXarxes socials03 medical and health sciences0302 clinical medicineHealth claims on food labelsBulosmedicineHumansDesinformació030212 general & internal medicineSARS-CoV-2Hoax030503 health policy & servicesPreventionSignificant differencePublic Health Environmental and Occupational HealthCOVID-19HoaxesCuraciónSalut públicaSociologiaPrevenciónSpainHealthFamily medicineCommunicable Disease ControlMisinformationFemaleDesinformaciónPublic aspects of medicineRA1-12700305 other medical sciencePsychologyCure
researchProduct

Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients.

2008

OBJECTIVE: This is a multicentre, open label, prospective non-randomized registry, with 9-month angiographic follow-up, conducted to evaluate the safety and effectiveness of drug-eluting stents (DES) when used in high restenosis risk patients from the real world. METHODS: From June 2004 to February 2005, a total of 1622 consecutive patients were enrolled to the Sicilian DES Registry, according to specific inclusion criteria. Both paclitaxel-eluting and sirolimus-eluting stents were used. The analysis was performed on 1472 patients because 150 patients were excluded from the study. The primary endpoint was to evaluate the rate of major adverse cardiac events (MACE) within 9 months after DES …

Malemedicine.medical_specialtyPaclitaxelCoronary angioplastyRegistry.Target vessel revascularizationCoronary DiseaseCoronary AngiographyCoronary artery diseaseCoronary RestenosisRestenosisClinical endpointMedicineHumansCumulative incidencecardiovascular diseasesMyocardial infarctionDrug eluting stentRegistriesAngioplasty Balloon CoronarySicilyAgedSirolimusEjection fractionbusiness.industryIncidence (epidemiology)Drug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseSurgeryFemaleCardiology and Cardiovascular MedicinebusinessMaceDiabetic AngiopathiesImmunosuppressive AgentsJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease.

2009

Objective: To investigate long-term outcomes of unprotected left main coronary artery (ULMCA) disease treatment using drug-eluting stents (DES). Background: In several studies, DES implantation in ULMCA appeared safe and effective at mid-term; however, to date, there is limited long-term data. Methods: All consecutive patients undergoing sirolimus- or paclitaxel-eluting stent implantation in ULMCA disease at a single institution were evaluated. The primary endpoint was long-term major adverse cardiac events (MACE) defined as cardiac death, nonfatal myocardial infarction, or target lesion revascularization (TLR). Stent thrombosis (ST), according to Academic Research Consortium definitions, w…

Malemedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentCoronary Artery DiseaseCoronary AngiographyRestenosisRecurrenceInternal medicineLong-term outcomes.medicineClinical endpointHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesMyocardial infarctionSurvival rateAgedProportional Hazards ModelsSirolimusChi-Square Distributionbusiness.industryHazard ratioEuroSCOREDrug-Eluting StentsGeneral MedicineLeft main coronary arterymedicine.diseaseSurgeryTreatment OutcomeDrug-eluting stentCardiologyFemaleDrug-eluting stentCardiology and Cardiovascular MedicinebusinessMaceFollow-Up StudiesCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct